Lyell presents positive initial clinical data from the phase 1-2 clinical trial of impt-314 for the treatment of b-cell lymphoma at the 2024 ash annual meeting

South san francisco, calif., dec. 09, 2024 (globe newswire) -- lyell immunopharma, inc. (nasdaq: lyel), a clinical-stage company advancing a pipeline of next-generation car t-cell therapies for patients with solid tumors or hematologic malignancies, today announced initial positive clinical data from the multi-center phase 1-2 study of impt-314 in patients with large b-cell lymphoma that is being presented at the 66th american society of hematology (ash) annual meeting. impt-314 is an autologous dual-targeting cd19/cd20 chimeric antigen receptor (car) t-cell product candidate being developed for patients with aggressive b-cell non-hodgkin lymphoma.
ASH Ratings Summary
ASH Quant Ranking